Orexo to explore strategic alternatives for commercialization in the USA

7 October 2012

Swedish specialty pharmaceutical company Orexo (STO:ORX), with a focus on innovative sublingual drug delivery technologies, said last week that it has retained Guggenheim Securities as its financial advisor to assist in the company’s review and evaluation of a full range of strategic alternatives.

The board of directors initiated this review in conjunction with the company’s ongoing evaluation of its US commercial plan, with the aim of enhancing both commercial prospects for Orexo’a products and shareholder value.

Based on the recent submission of a New Drug Application for Zubsolv (OX219; a novel combination of buprenorphine and naloxone) to the US Food and Drug Administration and the transfer of Abstral, the novel, rapidly-disintegrating, sublingual formulation of fentanyl, US commercial rights to Orexo from January 1, 2013 (The Pharma Letter June 4), Orexo expects to have two commercially available products in the USA in 2013.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK